1. Home
  2. JCE vs CERS Comparison

JCE vs CERS Comparison

Compare JCE & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JCE
  • CERS
  • Stock Information
  • Founded
  • JCE 2007
  • CERS 1991
  • Country
  • JCE United States
  • CERS United States
  • Employees
  • JCE N/A
  • CERS N/A
  • Industry
  • JCE Trusts Except Educational Religious and Charitable
  • CERS EDP Services
  • Sector
  • JCE Finance
  • CERS Technology
  • Exchange
  • JCE Nasdaq
  • CERS Nasdaq
  • Market Cap
  • JCE 269.8M
  • CERS 276.0M
  • IPO Year
  • JCE N/A
  • CERS 1997
  • Fundamental
  • Price
  • JCE $15.98
  • CERS $1.52
  • Analyst Decision
  • JCE
  • CERS Buy
  • Analyst Count
  • JCE 0
  • CERS 1
  • Target Price
  • JCE N/A
  • CERS $4.00
  • AVG Volume (30 Days)
  • JCE 49.7K
  • CERS 1.2M
  • Earning Date
  • JCE 01-01-0001
  • CERS 11-06-2025
  • Dividend Yield
  • JCE 9.26%
  • CERS N/A
  • EPS Growth
  • JCE N/A
  • CERS N/A
  • EPS
  • JCE N/A
  • CERS N/A
  • Revenue
  • JCE N/A
  • CERS $192,510,000.00
  • Revenue This Year
  • JCE N/A
  • CERS $19.07
  • Revenue Next Year
  • JCE N/A
  • CERS $12.03
  • P/E Ratio
  • JCE N/A
  • CERS N/A
  • Revenue Growth
  • JCE N/A
  • CERS 13.25
  • 52 Week Low
  • JCE $11.64
  • CERS $1.12
  • 52 Week High
  • JCE $14.28
  • CERS $2.24
  • Technical
  • Relative Strength Index (RSI)
  • JCE 63.88
  • CERS 51.07
  • Support Level
  • JCE $15.75
  • CERS $1.48
  • Resistance Level
  • JCE $16.02
  • CERS $1.55
  • Average True Range (ATR)
  • JCE 0.21
  • CERS 0.08
  • MACD
  • JCE 0.04
  • CERS -0.02
  • Stochastic Oscillator
  • JCE 90.70
  • CERS 42.86

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Share on Social Networks: